Key takeaways
Inpefa (sotagliflozin) and Jardiance (empagliflozin) are both medications used to lower the risk of heart-related problems in people with heart failure and chronic kidney disease (CKD). They also help lower blood sugar in people with Type 2 diabetes, but Inpefa is not specifically approved to treat diabetes itself. Inpefa is a sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2) inhibitor, while Jardiance is only an SGLT2 inhibitor. This means Inpefa works in both the kidneys and the gut, whereas Jardiance works only in the kidneys. Inpefa is taken as a 200 mg or 400 mg tablet once daily, while Jardiance is taken as a 10 mg or 25 mg tablet once daily. Both medications can cause urinary tract infections, yeast infections, and increased urination. Inpefa may also cause diarrhea due to its effects on the gut. Neither medication has a generic version available yet. If you take other diabetes medications, both Inpefa and Jardiance can increase the risk of low blood sugar.
